Read-Gene S.A. (WSE: RDG)
Health Care · Biotechnology · PL
zł4.97
-0.40% today · -15.2% 1Y
Read-Gene S.A. (WSE: RDG) operates in the Biotechnology industry within the Health Care sector. The company is valued at $15.87M.
Over the last twelve months the share price has lost 15.2%, trading between 4.57 and 6.90.
Tweenvest scores Read-Gene S.A. across four factors: quality 61/100, value 57/100, growth 99/100. Its strongest factor is growth.
RDG price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $15.87M
- Revenue (TTM)
- $4.44M
- P/E
- —
- EPS
- —
- Dividend yield
- —
- Beta (5Y)
- 0.26
- 52-week high
- zł6.90
- 52-week low
- zł4.57
- Avg volume (3M)
- —
- Shares outstanding
- 11.79M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €874.20 | +1.16% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.83 | +2.12% |
Figures last refreshed Aug 18, 2026.